Neo-DIANA: descriptive results of a prematurely terminated phase II trial of neoadjuvant atezolizumab, chemotherapy and bevacizumab in resectable EGFR-mutated NSCLC.
- DOI
- 10.21037/tlcr-2026-0711
- Published
- 2026 Aug 31
- Container
- Translational lung cancer research
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.21037/tlcr-2026-0711,
title = {Neo-DIANA: descriptive results of a prematurely terminated phase II trial of neoadjuvant atezolizumab, chemotherapy and bevacizumab in resectable EGFR-mutated NSCLC.},
author = {Collazo-Lorduy A and Calvo V and Nadal E and Provencio M},
year = {2026},
journal = {Translational lung cancer research},
doi = {10.21037/tlcr-2026-0711},
url = {https://doi.org/10.21037/tlcr-2026-0711}
}RIS
TY - JOUR TI - Neo-DIANA: descriptive results of a prematurely terminated phase II trial of neoadjuvant atezolizumab, chemotherapy and bevacizumab in resectable EGFR-mutated NSCLC. AU - Collazo-Lorduy A AU - Calvo V AU - Nadal E AU - Provencio M PY - 2026 JO - Translational lung cancer research DO - 10.21037/tlcr-2026-0711 UR - https://doi.org/10.21037/tlcr-2026-0711 ER -
APA
A, C., V, C., E, N., & M, P. (2026). Neo-DIANA: descriptive results of a prematurely terminated phase II trial of neoadjuvant atezolizumab, chemotherapy and bevacizumab in resectable EGFR-mutated NSCLC.. Translational lung cancer research. https://doi.org/10.21037/tlcr-2026-0711
Source records
- pubmed · retrieved 2026-09-26T11:11:24.595Z